Drug Profile
Research programme: antibody therapeutics - Merck/Teijin Pharma
Alternative Names: anti-tau inhibitors - Merck/Teijin PharmaLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Merck & Co; Teijin Pharma
- Class Antibodies; Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 25 May 2017 Merck and Teijin Pharma agree to co-develop and co-promote anti-tau inhibitors for Alzheimer's disease
- 25 May 2017 Preclinical trials in Alzheimer's disease in USA (unspecified route)